rapp id development of ra pid p oint of care test p latforms for i nfectious d iseases
Download
Skip this Video
Download Presentation
RAPP-ID Development of RA pid P oint-of-Care test P latforms for I nfectious D iseases

Loading in 2 Seconds...

play fullscreen
1 / 10

RAPP-ID Development of RA pid P oint-of-Care test P latforms for I nfectious D iseases - PowerPoint PPT Presentation


  • 170 Views
  • Uploaded on

RAPP-ID Development of RA pid P oint-of-Care test P latforms for I nfectious D iseases. Herman Goossens, MD, PhD Academic Coordinator University of Antwerp, Belgium Jorge Villacian, MD Project Coordinator Johnson & Johnson, Belgium.

loader
I am the owner, or an agent authorized to act on behalf of the owner, of the copyrighted work described.
capcha
Download Presentation

PowerPoint Slideshow about 'RAPP-ID Development of RA pid P oint-of-Care test P latforms for I nfectious D iseases' - ernst


An Image/Link below is provided (as is) to download presentation

Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.


- - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - -
Presentation Transcript
rapp id development of ra pid p oint of care test p latforms for i nfectious d iseases

RAPP-IDDevelopment of RApid Point-of-Care test Platforms for Infectious Diseases

Herman Goossens, MD, PhD Academic Coordinator

University of Antwerp, Belgium

Jorge Villacian, MD Project Coordinator

Johnson & Johnson, Belgium

why do we need better rapid point of care tests
Why do we need better Rapid Point-of-Care Tests?
  • There has been under-investment in rapid diagnostics for improving the quality of care for patients with suspected infections:
    • Diagnostics influence 60-70% of health care decision making but account for less than 5% of hospital costs (Lewin report 2006)
  • POCTs improve antibiotic targeting to only those who will benefit, thus reducing overuse:
    • The commonest reason for prescribing antibiotics in the community is acute cough, and these prescriptions virtually never benefit patients (Butler et al, BMJ 2009)
why do we need better rapid point of care tests3
Why do we need better Rapid Point-of-Care Tests?
  • POCTs enhance surveillance of pathogens and infectious diseases:
    • e.g. H1N1 flu pandemic
  • POCTs support rapid initiation and cessation of treatment:
    • Sepsis is associated with 7% increased mortality for every hour delay in the administration of appropriate antibiotics (Kumar el al, CCM 2006).
  • POCTs decrease the size and cost of antibacterial clinical trials:
    • We URGENTLY need new antibiotics (ECDC/EMA report 2009)
why did industry and academia fail
Why did Industry and Academia Fail?

Can you imagine the challenges of shrinking a huge laboratory filled with people and equipment onto a single chip the size of a matchbox?

Neither industry, nor academia can do this on their own!

Ziober et al. Head Neck 2008

overall objective
Overall Objective

RAPP-ID will develop a Point-of-Care Test (POCT) for rapid (hospital <2h, primary care <30min) detection of bacteria, mycobacteria, fungi, as well as viruses and host biomarkers by combining novel specific probes, novel methods of sample preparation, and demonstrated ultra-high sensitive detection methods. The platforms will also determine resistance to antimicrobial drugs

rapp id meets clearly defined clinician needs
RAPP-ID Meets Clearly Defined Clinician Needs

Sepsis

Lower Respiratory Tract Infections (LRTI)

Community-Acquired Pneumonia (CAP)

Ventilator-Associated Pneumonia (VAP)

Tuberculosis (TB)

consortium synergies
Consortium Synergies
  • Academic partners:
    • Expertise in European Projects
    • Innovative technologies
    • Clinical expertise
    • Samples/Laboratory capabilities
  • SME:
    • Innovative technologies
    • Flexible attitude
  • EFPIA
    • Industry perspective
    • Expertise in clinical development
    • Regulatory and communication expertise
    • Samples/Laboratory capabilities
why should rapp id succeed
Why Should RAPP-ID Succeed?
  • IMI is a unique instrument of joint academia-industry initiatives, and this is the ONLY way to successfully develop POCT for Infectious Diseases
  • RAPP-ID partners have built up experience in other EU funded projects (GRACE, InTopSens, TheraEDGE, ...)
  • RAPP-ID provides a unique combination of a whole range of novel assays and technologies
  • POCT development will not only be “pathogen or technologically driven’ but also designed to meet clearly defined clinical needs with optimal integration and implementation into diagnostic/clinical algorithms and healthcare programs
ad